-- --------------------------------------------------------
-- Host                          :127.0.0.1
-- Server version                :5.5.24-log - MySQL Community Server (GPL)
-- Server OS                     :Win64
-- HeidiSQL Version              :7.0.0.4249
-- Created                       :2013-05-06 20:02:28
-- --------------------------------------------------------

/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET NAMES utf8 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;

-- Dumping database structure for rct
DROP DATABASE IF EXISTS `rct`;
CREATE DATABASE IF NOT EXISTS `rct` /*!40100 DEFAULT CHARACTER SET latin1 */;
USE `rct`;


-- Dumping structure for table rct.ask
DROP TABLE IF EXISTS `ask`;
CREATE TABLE IF NOT EXISTS `ask` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `team_id` int(10) unsigned NOT NULL DEFAULT '0',
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `content` text,
  `comment` text,
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM AUTO_INCREMENT=2 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.ask: 1 rows
DELETE FROM `ask`;
/*!40000 ALTER TABLE `ask` DISABLE KEYS */;
INSERT INTO `ask` (`id`, `user_id`, `team_id`, `city_id`, `content`, `comment`, `create_time`) VALUES
	(1, 7, 4, 1, 'This is a question', NULL, 1365738247);
/*!40000 ALTER TABLE `ask` ENABLE KEYS */;


-- Dumping structure for table rct.card
DROP TABLE IF EXISTS `card`;
CREATE TABLE IF NOT EXISTS `card` (
  `id` varchar(16) NOT NULL,
  `code` varchar(16) DEFAULT NULL,
  `partner_id` int(10) unsigned NOT NULL DEFAULT '0',
  `team_id` int(10) unsigned NOT NULL DEFAULT '0',
  `order_id` int(10) unsigned NOT NULL DEFAULT '0',
  `credit` int(10) unsigned NOT NULL DEFAULT '0',
  `consume` enum('Y','N') NOT NULL DEFAULT 'N',
  `ip` varchar(16) DEFAULT NULL,
  `begin_time` int(10) unsigned NOT NULL DEFAULT '0',
  `end_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.card: 0 rows
DELETE FROM `card`;
/*!40000 ALTER TABLE `card` DISABLE KEYS */;
/*!40000 ALTER TABLE `card` ENABLE KEYS */;


-- Dumping structure for table rct.category
DROP TABLE IF EXISTS `category`;
CREATE TABLE IF NOT EXISTS `category` (
  `id` int(10) unsigned NOT NULL AUTO_INCREMENT,
  `zone` varchar(16) DEFAULT NULL,
  `czone` varchar(32) DEFAULT NULL,
  `name` varchar(32) DEFAULT NULL,
  `ename` varchar(16) DEFAULT NULL,
  `letter` char(1) DEFAULT NULL,
  `sort_order` int(11) NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_zne` (`zone`,`name`,`ename`)
) ENGINE=MyISAM AUTO_INCREMENT=5 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.category: 4 rows
DELETE FROM `category`;
/*!40000 ALTER TABLE `category` DISABLE KEYS */;
INSERT INTO `category` (`id`, `zone`, `czone`, `name`, `ename`, `letter`, `sort_order`) VALUES
	(1, 'city', '', 'San&nbsp;Diego', 'San&nbsp;digeo', 'S', 0),
	(2, 'city', '', 'Los&nbsp;Angeles', 'Los&nbsp;angeles', 'L', 0),
	(3, 'city', '', 'Boston', 'Boston', 'B', 0),
	(4, 'city', '', 'Pittsburgh', 'pittsburgh', 'P', 0);
/*!40000 ALTER TABLE `category` ENABLE KEYS */;


-- Dumping structure for table rct.coupon
DROP TABLE IF EXISTS `coupon`;
CREATE TABLE IF NOT EXISTS `coupon` (
  `id` varchar(12) NOT NULL DEFAULT '',
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `partner_id` int(10) unsigned NOT NULL DEFAULT '0',
  `team_id` int(10) unsigned NOT NULL DEFAULT '0',
  `order_id` int(10) unsigned NOT NULL DEFAULT '0',
  `type` enum('consume','credit') NOT NULL DEFAULT 'consume',
  `credit` int(10) unsigned NOT NULL DEFAULT '0',
  `secret` varchar(10) DEFAULT NULL,
  `consume` enum('Y','N') NOT NULL DEFAULT 'N',
  `ip` varchar(16) DEFAULT NULL,
  `sms` int(10) unsigned NOT NULL DEFAULT '0',
  `expire_time` int(10) unsigned NOT NULL DEFAULT '0',
  `consume_time` int(10) unsigned NOT NULL DEFAULT '0',
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.coupon: 0 rows
DELETE FROM `coupon`;
/*!40000 ALTER TABLE `coupon` DISABLE KEYS */;
/*!40000 ALTER TABLE `coupon` ENABLE KEYS */;


-- Dumping structure for table rct.feedback
DROP TABLE IF EXISTS `feedback`;
CREATE TABLE IF NOT EXISTS `feedback` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `category` enum('suggest','seller') NOT NULL DEFAULT 'suggest',
  `title` varchar(128) DEFAULT NULL,
  `contact` varchar(255) DEFAULT NULL,
  `content` text,
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM AUTO_INCREMENT=5 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.feedback: 4 rows
DELETE FROM `feedback`;
/*!40000 ALTER TABLE `feedback` DISABLE KEYS */;
INSERT INTO `feedback` (`id`, `city_id`, `user_id`, `category`, `title`, `contact`, `content`, `create_time`) VALUES
	(1, 3, 0, 'seller', 'DBMI', 'dbmi@ucsd.edu', 'Bacterial Vaginosis in Pregnancy: Detection by Weekly Vaginal pH Testing', 1365734193),
	(2, 1, 0, 'seller', 'UCSD DBMI', 'dbmi@ucsd.edu', 'Early Connections, Early Detection and Intervention in Infants at Risk for Early Connections, Early Detection and Intervention in Infants at Risk for Autism', 1365736374),
	(3, 1, 0, 'seller', 'UCSD DBMI', 'dbmi.ucsd.edu', 'Early Connections, Early Detection and Intervention in Infants at Risk for Autism', 1365736449),
	(4, 1, 0, 'seller', 'UCSDDBMI', 'dbmi@ucsd.edu', 'Collection of Samples and Data for the National Marrow Donor Program Repository', 1365736834);
/*!40000 ALTER TABLE `feedback` ENABLE KEYS */;


-- Dumping structure for table rct.flow
DROP TABLE IF EXISTS `flow`;
CREATE TABLE IF NOT EXISTS `flow` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `admin_id` int(10) unsigned NOT NULL DEFAULT '0',
  `detail_id` varchar(32) DEFAULT NULL,
  `direction` enum('income','expense') NOT NULL DEFAULT 'income',
  `money` double(10,2) NOT NULL DEFAULT '0.00',
  `action` varchar(16) NOT NULL DEFAULT 'buy',
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.flow: 0 rows
DELETE FROM `flow`;
/*!40000 ALTER TABLE `flow` DISABLE KEYS */;
/*!40000 ALTER TABLE `flow` ENABLE KEYS */;


-- Dumping structure for table rct.friendlink
DROP TABLE IF EXISTS `friendlink`;
CREATE TABLE IF NOT EXISTS `friendlink` (
  `id` int(11) NOT NULL AUTO_INCREMENT,
  `title` varchar(32) DEFAULT NULL,
  `url` varchar(255) DEFAULT NULL,
  `logo` varchar(255) DEFAULT NULL,
  `sort_order` int(11) DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.friendlink: 0 rows
DELETE FROM `friendlink`;
/*!40000 ALTER TABLE `friendlink` DISABLE KEYS */;
/*!40000 ALTER TABLE `friendlink` ENABLE KEYS */;


-- Dumping structure for table rct.invite
DROP TABLE IF EXISTS `invite`;
CREATE TABLE IF NOT EXISTS `invite` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `admin_id` int(10) unsigned NOT NULL DEFAULT '0',
  `user_ip` varchar(16) DEFAULT NULL,
  `other_user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `other_user_ip` varchar(16) DEFAULT NULL,
  `team_id` int(10) unsigned NOT NULL DEFAULT '0',
  `pay` enum('Y','N') NOT NULL DEFAULT 'N',
  `credit` int(10) unsigned NOT NULL DEFAULT '0',
  `buy_time` int(10) unsigned NOT NULL DEFAULT '0',
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_uo` (`user_id`,`other_user_id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.invite: 0 rows
DELETE FROM `invite`;
/*!40000 ALTER TABLE `invite` DISABLE KEYS */;
/*!40000 ALTER TABLE `invite` ENABLE KEYS */;


-- Dumping structure for table rct.order
DROP TABLE IF EXISTS `order`;
CREATE TABLE IF NOT EXISTS `order` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `pay_id` varchar(32) DEFAULT NULL,
  `service` varchar(16) NOT NULL DEFAULT 'alipay',
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `admin_id` int(10) unsigned NOT NULL DEFAULT '0',
  `team_id` int(10) unsigned NOT NULL DEFAULT '0',
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `card_id` varchar(16) DEFAULT NULL,
  `state` enum('unpay','pay') NOT NULL DEFAULT 'unpay',
  `quantity` int(10) unsigned NOT NULL DEFAULT '1',
  `realname` varchar(32) DEFAULT NULL,
  `mobile` varchar(128) DEFAULT NULL,
  `zipcode` char(6) DEFAULT NULL,
  `address` varchar(128) DEFAULT NULL,
  `express` enum('Y','N') NOT NULL DEFAULT 'Y',
  `express_xx` varchar(128) DEFAULT NULL,
  `express_id` int(10) unsigned NOT NULL DEFAULT '0',
  `express_no` varchar(32) DEFAULT NULL,
  `price` double(10,2) NOT NULL DEFAULT '0.00',
  `money` double(10,2) NOT NULL DEFAULT '0.00',
  `origin` double(10,2) NOT NULL DEFAULT '0.00',
  `credit` double(10,2) NOT NULL DEFAULT '0.00',
  `card` double(10,2) NOT NULL DEFAULT '0.00',
  `fare` double(10,2) NOT NULL DEFAULT '0.00',
  `remark` text,
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_p` (`pay_id`)
) ENGINE=MyISAM AUTO_INCREMENT=7 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.order: 6 rows
DELETE FROM `order`;
/*!40000 ALTER TABLE `order` DISABLE KEYS */;
INSERT INTO `order` (`id`, `pay_id`, `service`, `user_id`, `admin_id`, `team_id`, `city_id`, `card_id`, `state`, `quantity`, `realname`, `mobile`, `zipcode`, `address`, `express`, `express_xx`, `express_id`, `express_no`, `price`, `money`, `origin`, `credit`, `card`, `fare`, `remark`, `create_time`) VALUES
	(1, NULL, 'credit', 1, 0, 4, 1, NULL, 'pay', 1, NULL, NULL, NULL, NULL, 'N', NULL, 0, NULL, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, '', 1364965687),
	(2, NULL, 'credit', 2, 0, 1090, 0, NULL, 'pay', 1, NULL, NULL, NULL, NULL, 'N', NULL, 0, NULL, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, '', 1365482404),
	(3, NULL, 'credit', 6, 0, 1035, 0, NULL, 'pay', 1, NULL, NULL, NULL, NULL, 'N', NULL, 0, NULL, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, '', 1365720713),
	(4, NULL, 'alipay', 7, 0, 4, 1, NULL, 'unpay', 1, NULL, NULL, NULL, NULL, 'N', NULL, 0, NULL, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, '', 1365738687),
	(5, NULL, 'credit', 8, 0, 4, 1, NULL, 'pay', 1, NULL, NULL, NULL, NULL, 'N', NULL, 0, NULL, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 'This is a remark', 1365738967),
	(6, NULL, 'credit', 8, 0, 1, 1, NULL, 'pay', 1, NULL, NULL, NULL, NULL, 'N', NULL, 0, NULL, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, '', 1365739300);
/*!40000 ALTER TABLE `order` ENABLE KEYS */;


-- Dumping structure for table rct.page
DROP TABLE IF EXISTS `page`;
CREATE TABLE IF NOT EXISTS `page` (
  `id` varchar(16) NOT NULL,
  `value` text,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.page: 1 rows
DELETE FROM `page`;
/*!40000 ALTER TABLE `page` DISABLE KEYS */;
INSERT INTO `page` (`id`, `value`) VALUES
	('help_faqs', '<span LANG="EN"><font FACE="Cambria" COLOR="#66CCFF"><b>\r\n<p ALIGN="LEFT" DIR="LTR">What is IMPACT web service?<br>\r\n</b></font><font FACE="Cambria">\r\nIMPACT is the acronym of the <u>I</u>nteractive <u>M</u>atching\r\n<u>P</u>atients <u>A</u>nd randomized <u>C</u>linical <u>T</u>rials. The IMPACT web service proposes a new paradigm of \r\nrecruiting participants for randomized clinical trials (RCT\'s) in a dynamic and \r\ninteractive manner, as motivated by the successful commercial group discount \r\nmarket (www.groupon.com). Using our IMPACT web service, researchers can reach \r\nout and better motivate a larger patient population for recruitment. Moreover \r\npatients have easier and more active ways to learn and participate in studies of \r\ninterest. Stakeholders, such as funding agencies can also play an active role in \r\nthe RCT enrollment process.</p>\r\n</font>\r\n<p ALIGN="LEFT" DIR="LTR"></p>\r\n<font FACE="Cambria" COLOR="#66CCFF"><b>\r\n<p ALIGN="LEFT" DIR="LTR">What can I do with IMPACT web service?<br>\r\n</b></font><font FACE="Cambria">\r\nIn IMPACT web service,&nbsp; you can browse as a \r\nguest, register as a user, subscrib through email, joining a randomized clinical \r\ntrial, raise a question, suggest a new study, collect invitation rewards and \r\nmuch more.</font></p>\r\n<p ALIGN="LEFT" DIR="LTR"><font FACE="Cambria" COLOR="#66CCFF"><b>\r\nWhat can I do as a guest user?<br>\r\n</b></font><font FACE="Cambria">\r\nAs a first time user,&nbsp; You can browse the impact web service as a guest \r\nwith limited access.&nbsp; For example, you can browse an existing randomized \r\nclinical trial and view relevant information about the study. Guest users also \r\nhave the opportunity to suggest a new study by clicking the corresponding \r\nsidebar widget. Then, the IMPACT web service will navigate you to the \r\nappropriate study suggestion page, where you will be required to provide your \r\nname, contact information and any additional details. Guest users can also \r\nsubscribe to the impact web service by providing their email in the sidebar \r\nwidget labeled &quot;want to learn more studies&quot;. By subscribing to our mailing list. \r\nsubscribers will receive the latest updates from our impact web service.</font></p>\r\n<p ALIGN="LEFT" DIR="LTR"></span><font FACE="Cambria">\r\n<font color="#66CCFF"><b>Who will review my suggests?<br>\r\n</b></font><span LANG="EN">Each suggestion will be assessed through a collective \r\nreview process and evaluated by community members. including other patients, \r\nresearchers, and funding agencies. to determine its validity.</span></font></p>\r\n<p ALIGN="LEFT" DIR="LTR"><font FACE="Cambria">\r\n<font color="#66CCFF"><b>What do I need to be an IMPACT user?<br>\r\n</b></font><span LANG="EN">Guest users can register for the impact web service \r\nby providing their email, a user name, a password and a phone number.&nbsp; They \r\ncan also designate a city and subscribe to its corresponding mailing list. After \r\nregistering, the user will be automatically logged into the system.</span></font></p>\r\n<p ALIGN="LEFT" DIR="LTR"><font FACE="Cambria">\r\n<font color="#66CCFF"><b>What can I do as an IMPACT user?<br>\r\n</b></font><span LANG="EN">Once logged in, a user has access to more functions. \r\nFor example, this sidebar widget can be used for inviting friends through an \r\ninvitation link and earning rewards. Moreover, a user can raise a question for a \r\nspecific randomized clinical trial through our Q and A widget.&nbsp; The \r\nsubmitted questions will be reviewed and selectively answered by the researchers \r\nor stakeholders in the community based on the popularity.</span></font></p>\r\n<p ALIGN="LEFT" DIR="LTR"><font FACE="Cambria">\r\n<font color="#66CCFF"><b>What is a RCT?<br>\r\n</b></font><span LANG="EN">RCT is <u>R</u>andomized <u>C</u>linical <u>T</u>rials.</span></font></p>\r\n<p ALIGN="LEFT" DIR="LTR"><font FACE="Cambria">\r\n<font color="#66CCFF"><b>How can I join a RCT?<br>\r\n</b></font><span LANG="EN">A user can join a study by clicking the join button. \r\nIn the next page, the user can click the continue button to submit remarks for \r\nthe given study. <br>\r\nThe user has the option to review remarks, or even return to the previous page \r\nto make revisions. If everything is okay, the user can click the continue \r\nbutton. followed by the &quot;ok and join&quot; button, to finish enrolling for a study.</span></font></p>\r\n<p ALIGN="LEFT" DIR="LTR"><font FACE="Cambria">\r\n<font color="#66CCFF"><b>Where can I find my joined RCTs?<br>\r\n</b></font>After joining a study, the user can click the &quot;joined list&quot; link to \r\ncheck its status and get more information under the &quot;My Project\' tab.\r\n</font></p>\r\n<p ALIGN="LEFT" DIR="LTR"><font FACE="Cambria">\r\n<font color="#66CCFF"><b>Where can I update my account information?<br>\r\n</b></font>Under the &quot;account info&quot; tab, the user has the option to update \r\npersonal information. </p>\r\n<p ALIGN="LEFT" DIR="LTR">　</p>\r\n<p ALIGN="LEFT" DIR="LTR">　</p>\r\n</font>');
/*!40000 ALTER TABLE `page` ENABLE KEYS */;


-- Dumping structure for table rct.partner
DROP TABLE IF EXISTS `partner`;
CREATE TABLE IF NOT EXISTS `partner` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `username` varchar(32) DEFAULT NULL,
  `password` varchar(32) DEFAULT NULL,
  `title` varchar(128) DEFAULT NULL,
  `homepage` varchar(128) DEFAULT NULL,
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `bank_name` varchar(128) DEFAULT NULL,
  `bank_no` varchar(128) DEFAULT NULL,
  `bank_user` varchar(128) DEFAULT NULL,
  `location` text NOT NULL,
  `contact` varchar(32) DEFAULT NULL,
  `phone` varchar(18) DEFAULT NULL,
  `address` varchar(128) DEFAULT NULL,
  `addres` varchar(128) DEFAULT NULL,
  `other` text,
  `mobile` varchar(12) DEFAULT NULL,
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_ct` (`city_id`,`title`),
  UNIQUE KEY `UNQ_u` (`username`)
) ENGINE=MyISAM AUTO_INCREMENT=3 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.partner: 2 rows
DELETE FROM `partner`;
/*!40000 ALTER TABLE `partner` DISABLE KEYS */;
INSERT INTO `partner` (`id`, `username`, `password`, `title`, `homepage`, `city_id`, `bank_name`, `bank_no`, `bank_user`, `location`, `contact`, `phone`, `address`, `addres`, `other`, `mobile`, `user_id`, `create_time`) VALUES
	(1, 'UCSD', 'e7fe8b88db51d86ef2f5e169144b9c1b', 'UCSD health system', 'http://health.ucsd.edu/clinicaltrials/Pages/default.aspx', 0, '', '', '', '', '', '8586577000', '9500 Gilman Dr., La Jolla, CA 92093', NULL, '', '', 1, 1364958191),
	(2, 'clinicaltrial.org', NULL, 'clinicaltrial.org', 'http://ClinicalTrials.gov/', 0, NULL, NULL, NULL, '', NULL, NULL, NULL, NULL, NULL, NULL, 1, 1364958191);
/*!40000 ALTER TABLE `partner` ENABLE KEYS */;


-- Dumping structure for table rct.pay
DROP TABLE IF EXISTS `pay`;
CREATE TABLE IF NOT EXISTS `pay` (
  `id` varchar(32) NOT NULL DEFAULT '',
  `order_id` int(10) unsigned NOT NULL DEFAULT '0',
  `bank` varchar(32) DEFAULT NULL,
  `money` double(10,2) DEFAULT NULL,
  `currency` enum('CNY','USD') NOT NULL DEFAULT 'CNY',
  `service` varchar(16) NOT NULL DEFAULT 'alipay',
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_o` (`order_id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.pay: 0 rows
DELETE FROM `pay`;
/*!40000 ALTER TABLE `pay` DISABLE KEYS */;
/*!40000 ALTER TABLE `pay` ENABLE KEYS */;


-- Dumping structure for table rct.smssubscribe
DROP TABLE IF EXISTS `smssubscribe`;
CREATE TABLE IF NOT EXISTS `smssubscribe` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `mobile` varchar(18) DEFAULT NULL,
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `secret` char(6) DEFAULT NULL,
  `enable` enum('Y','N') NOT NULL DEFAULT 'N',
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_e` (`mobile`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.smssubscribe: 0 rows
DELETE FROM `smssubscribe`;
/*!40000 ALTER TABLE `smssubscribe` DISABLE KEYS */;
/*!40000 ALTER TABLE `smssubscribe` ENABLE KEYS */;


-- Dumping structure for table rct.subscribe
DROP TABLE IF EXISTS `subscribe`;
CREATE TABLE IF NOT EXISTS `subscribe` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `email` varchar(128) DEFAULT NULL,
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `secret` varchar(32) DEFAULT NULL,
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_e` (`email`)
) ENGINE=MyISAM AUTO_INCREMENT=64 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.subscribe: 15 rows
DELETE FROM `subscribe`;
/*!40000 ALTER TABLE `subscribe` DISABLE KEYS */;
INSERT INTO `subscribe` (`id`, `email`, `city_id`, `secret`) VALUES
	(63, 'xiaoqian.jiang@gmail.com', 1, '53212540772f061cda0f91c486725093'),
	(23, 'wsasyz@hotmail.com', 4, '788a80f35122764aca5f4757d44b8c7b'),
	(26, 'lj.cui@hotmail.com', 3, '603c4e1963ea0a43fb13c5caf356f4c4'),
	(27, 'wsasyz003@hotmail.com', 3, '1d40f6f87cfaf1dc45fccd51546d39ed'),
	(30, 'alhsieh@ucsd.edu', 1, '7302a581c96952a19826608dae2fbb8d'),
	(34, 'dbmi@ucsd.edu', 1, '40aaa9a1a6259bd2561e41afd2737204'),
	(32, 'dsdsfa@uds.esdf', 1, '54126e6c46dd08b00c5b06460b5f3d56'),
	(35, 'ucsd_dbmi@ucsd.edu', 1, 'a69322198f5421729a66c6fb4410033a'),
	(37, 'ucsd_dbmi1@ucsd.edu', 1, 'e003e27fe89132798d8a6b2935c84c00'),
	(39, 'ucsddbmi@ucsd.edu', 1, '639dc999016e83312c75a0b3467f9c47'),
	(40, 'abc@ucsd.edu', 1, 'fff4810094aedd2394d710527c1a1f14'),
	(41, 'dbmiucsd@ucsd.edu', 1, '0cf98c091d01bf8982e4a5e514f35963'),
	(45, 'sdfs@sdfa.com', 1, '71e2537015a7eb9a692b46034378732b'),
	(46, 'b8sevqw3yu24xoo@hotmail.com', 3, '65398e686bf887dcff7802adebef5a38'),
	(47, 'tqspde@uhynzo.com', 3, 'b51ecf1ecf513468c927883138ee740d');
/*!40000 ALTER TABLE `subscribe` ENABLE KEYS */;


-- Dumping structure for table rct.system
DROP TABLE IF EXISTS `system`;
CREATE TABLE IF NOT EXISTS `system` (
  `id` enum('1') NOT NULL DEFAULT '1',
  `value` text,
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.system: 1 rows
DELETE FROM `system`;
/*!40000 ALTER TABLE `system` DISABLE KEYS */;
INSERT INTO `system` (`id`, `value`) VALUES
	('1', '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');
/*!40000 ALTER TABLE `system` ENABLE KEYS */;


-- Dumping structure for table rct.team
DROP TABLE IF EXISTS `team`;
CREATE TABLE IF NOT EXISTS `team` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `title` varchar(128) DEFAULT NULL,
  `summary` text,
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `group_id` int(10) unsigned NOT NULL DEFAULT '0',
  `partner_id` int(10) unsigned NOT NULL DEFAULT '0',
  `system` enum('Y','N') NOT NULL DEFAULT 'Y',
  `team_price` double(10,2) NOT NULL DEFAULT '0.00',
  `market_price` double(10,2) NOT NULL DEFAULT '0.00',
  `product` varchar(128) DEFAULT NULL,
  `per_number` int(10) unsigned NOT NULL DEFAULT '1',
  `min_number` int(10) unsigned NOT NULL DEFAULT '1',
  `max_number` int(10) unsigned NOT NULL DEFAULT '0',
  `now_number` int(10) unsigned NOT NULL DEFAULT '0',
  `image` varchar(128) DEFAULT NULL,
  `image1` varchar(128) DEFAULT NULL,
  `image2` varchar(128) DEFAULT NULL,
  `flv` varchar(128) DEFAULT NULL,
  `mobile` varchar(16) DEFAULT NULL,
  `credit` int(10) unsigned NOT NULL DEFAULT '0',
  `card` int(10) unsigned NOT NULL DEFAULT '0',
  `fare` int(10) unsigned NOT NULL DEFAULT '0',
  `address` varchar(128) DEFAULT NULL,
  `detail` text,
  `systemreview` text,
  `userreview` text,
  `notice` text,
  `express` text,
  `delivery` enum('coupon','express','pickup') NOT NULL DEFAULT 'coupon',
  `state` enum('none','success','soldout','failure','refund') NOT NULL DEFAULT 'none',
  `conduser` enum('Y','N') NOT NULL DEFAULT 'Y',
  `buyonce` enum('Y','N') NOT NULL DEFAULT 'Y',
  `team_type` varchar(20) DEFAULT 'normal',
  `expire_time` int(10) unsigned NOT NULL DEFAULT '0',
  `begin_time` int(10) unsigned NOT NULL DEFAULT '0',
  `end_time` int(10) unsigned NOT NULL DEFAULT '0',
  `close_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM AUTO_INCREMENT=2001 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.team: 103 rows
DELETE FROM `team`;
/*!40000 ALTER TABLE `team` DISABLE KEYS */;
INSERT INTO `team` (`id`, `user_id`, `title`, `summary`, `city_id`, `group_id`, `partner_id`, `system`, `team_price`, `market_price`, `product`, `per_number`, `min_number`, `max_number`, `now_number`, `image`, `image1`, `image2`, `flv`, `mobile`, `credit`, `card`, `fare`, `address`, `detail`, `systemreview`, `userreview`, `notice`, `express`, `delivery`, `state`, `conduser`, `buyonce`, `team_type`, `expire_time`, `begin_time`, `end_time`, `close_time`) VALUES
	(1, 1, '24-hr Intraocular Pressure (IOP) Patterns of Glaucoma Patients After Selective Laser Trabeculoplasty (SLT) ', 'Interventions:	 Device: SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish\r\nPurpose:	 The purpose of this study is to determine the relationship between Intraocular Pressure (IOP) fluctuations of glaucoma patients as recorded with an IOP-sensing contact lens (SENSIMED Triggerfish®), during two 24-hour periods after selective laser trabeculoplasty (SLT) for routine treatment of glaucoma.', 1, 0, 1, 'Y', 0.00, 0.00, 'rct', 1, 100, 0, 1, 'team/2013/0403/13650073238645_BW.png', NULL, NULL, '', '', 0, 0, 5, '', '', '', '', '<table class="CT_Details" border="0" style="margin: 0px; padding: 0px; font-size: 12px; color: rgb(51, 51, 51); font-family: Arial, Helvetica, sans-serif; line-height: 21px; background-color: rgb(232, 232, 232);"><tbody style="margin: 0px; padding: 0px;"><tr style="margin: 0px; padding: 0px;"><td class="CT_Details_Left" style="margin: 0px; padding: 0px; font-family: verdana, arial, helvetica, sans-serif; vertical-align: top; color: rgb(45, 132, 175); width: 120px; font-weight: bold;">Eligibility</td><td class="CT_Details_Right" style="margin: 0px; padding: 0px; font-size: 8pt; font-family: verdana, arial, helvetica, sans-serif; width: 400px;"><span style="margin: 0px; padding: 0px;">Ages Eligible:&nbsp;18 Years</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Genders Eligible:&nbsp; Both</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Accepts Healthy Volunteers:&nbsp; No</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Inclusion Criteria:</span><ul style="margin: 0px 0px 8px; padding: 0px 0px 0px 20px; list-style: none;"><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Subjects must correspond to all other inclusion criteria in order to be eligible for the investigation. - Subject is able to comply with the study procedures - 18-80 years old - Subjects diagnosed with glaucoma, based on presence of repeatable visual field loss and/or glaucomatous optic neuropathy based on masked review of optic disc stereophotographs and under ocular hypotensive treatment, or diagnosed with ocular hypertension, with an IOP of &gt; 22 mmHg at the screening visit and under ocular hypotensive treatment. - Subject has consented to be in the trial - Visual acuity of 20/200 or better - Ability to understand the character and individual consequences of the study - For women of childbearing potential, adequate contraception</li></ul>Exclusion Criteria:<ul style="margin: 0px 0px 8px; padding: 0px 0px 0px 20px; list-style: none;"><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Subjects presenting with any of the following criteria will not be included in the trial: - Subjects with contraindications for wearing contact lenses - Severe dry eye syndrome - Keratoconus or other corneal abnormality - Conjunctival or intraocular inflammation - Eye surgery prior to and throughout the study. - Full frame metal glasses during SENSIMED Triggerfish® monitoring - Known hypersensitivity to silicone, plaster or ocular anesthesia (proparacaine) - Pregnancy and lactation - Simultaneous participation in other clinical studies</li></ul></td></tr></tbody></table>', '', 'coupon', 'none', 'Y', 'Y', 'normal', 1382927600, 1364792400, 1397365200, 0),
	(2, 1, 'A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer', 'Conditions:	 Advanced Prostate Cancer, Prostatic Neoplasms\r\nInterventions	 Biological: sipuleucel-T\r\nPurpose:	 The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE) therapy, and to follow all subjects for survival.', 1, 0, 1, 'Y', 0.00, 0.00, 'RCT', 1, 50, 0, 0, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '', '', '', '<table class="CT_Details" border="0" style="margin: 0px; padding: 0px; font-size: 12px; color: rgb(51, 51, 51); font-family: Arial, Helvetica, sans-serif; line-height: 21px; background-color: rgb(232, 232, 232);"><tbody style="margin: 0px; padding: 0px;"><tr style="margin: 0px; padding: 0px;"><td class="CT_Details_Left" style="margin: 0px; padding: 0px; font-family: verdana, arial, helvetica, sans-serif; vertical-align: top; color: rgb(45, 132, 175); width: 120px; font-weight: bold;">Eligibility</td><td class="CT_Details_Right" style="margin: 0px; padding: 0px; font-size: 8pt; font-family: verdana, arial, helvetica, sans-serif; width: 400px;"><span style="margin: 0px; padding: 0px;">Ages Eligible:&nbsp;18 Years</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Genders Eligible:&nbsp; Male</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Accepts Healthy Volunteers:&nbsp; No</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Inclusion Criteria:</span><ul style="margin: 0px 0px 8px; padding: 0px 0px 0px 20px; list-style: none;"><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">subjects must be at least 18 years of age</li><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment</li><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">subjects must understand and sign an informed consent form</li></ul>Exclusion Criteria:<ul style="margin: 0px 0px 8px; padding: 0px 0px 0px 20px; list-style: none;"><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">none</li></ul></td></tr><tr id="ctl00_SPWebPartManager1_g_d1747a04_e80e_456a_b620_87654bcf82cd_ctl00_trLocation" style="margin: 0px; padding: 0px;"><td class="CT_Details_Left" style="margin: 0px; padding: 0px; font-family: verdana, arial, helvetica, sans-serif; vertical-align: top; color: rgb(45, 132, 175); width: 120px; font-weight: bold;">Study Location</td><td class="CT_Details_Right" style="margin: 0px; padding: 0px; font-size: 8pt; font-family: verdana, arial, helvetica, sans-serif; width: 400px;"><div style="margin: 0px; padding: 0px;"><span style="margin: 0px; padding: 0px; white-space: nowrap;">UCSD Moores Cancer Center</span><div style="margin: 0px; padding: 0px;">La Jolla, California, 92093-0820</div></div></td></tr><tr style="margin: 0px; padding: 0px;"><td class="CT_Details_Left" style="margin: 0px; padding: 0px; font-family: verdana, arial, helvetica, sans-serif; vertical-align: top; color: rgb(45, 132, 175); width: 120px; font-weight: bold;">Contact</td><td class="CT_Details_Right" style="margin: 0px; padding: 0px; font-size: 8pt; font-family: verdana, arial, helvetica, sans-serif; width: 400px;"><span id="ctl00_SPWebPartManager1_g_d1747a04_e80e_456a_b620_87654bcf82cd_ctl00_lblContactName" style="margin: 0px; padding: 0px;">Arlene Araneta</span><br style="margin: 0px; padding: 0px;" /><span id="ctl00_SPWebPartManager1_g_d1747a04_e80e_456a_b620_87654bcf82cd_ctl00_lblContactPhone" style="margin: 0px; padding: 0px;">858-822-5374</span><br style="margin: 0px; padding: 0px;" /><a id="ctl00_SPWebPartManager1_g_d1747a04_e80e_456a_b620_87654bcf82cd_ctl00_lnkContactEmail" style="margin: 0px; padding: 0px; color: rgb(86, 155, 190);">aareneta@ucsd.edu</a></td></tr></tbody></table>', '', 'coupon', 'none', 'Y', 'Y', 'normal', 1382927600, 1364792400, 1397365200, 0),
	(4, 1, 'Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma', 'Conditions:	 Hepatocellular Carcinoma\r\nInterventions:	 Drug: Axitinib (AG-013736)\r\nDrug: Placebo\r\nPhase	 Phase 2\r\nPurpose:	 The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.', 1, 0, 1, 'Y', 0.00, 0.00, 'rct', 1, 10, 0, 2, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '', '', '', '<table class="CT_Details" border="0" style="margin: 0px; padding: 0px; font-size: 12px; color: rgb(51, 51, 51); font-family: Arial, Helvetica, sans-serif; line-height: 21px; background-color: rgb(232, 232, 232);"><tbody style="margin: 0px; padding: 0px;"><tr style="margin: 0px; padding: 0px;"><td class="CT_Details_Left" style="margin: 0px; padding: 0px; font-family: verdana, arial, helvetica, sans-serif; vertical-align: top; color: rgb(45, 132, 175); width: 120px; font-weight: bold;">Eligibility</td><td class="CT_Details_Right" style="margin: 0px; padding: 0px; font-size: 8pt; font-family: verdana, arial, helvetica, sans-serif; width: 400px;"><span style="margin: 0px; padding: 0px;">Ages Eligible:&nbsp;18 Years</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Genders Eligible:&nbsp; Both</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Accepts Healthy Volunteers:&nbsp; No</span>&nbsp;<br style="margin: 0px; padding: 0px;" /><span style="margin: 0px; padding: 0px;">Inclusion Criteria:</span><ul style="margin: 0px 0px 8px; padding: 0px 0px 0px 20px; list-style: none;"><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Locally advanced or metastatic HCC</li><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib.</li><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Child-Pugh Class A or B (score 7 only) disease.</li></ul>Exclusion Criteria:<ul style="margin: 0px 0px 8px; padding: 0px 0px 0px 20px; list-style: none;"><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Prior treatment of advanced HCC with more than one prior first-line systemic therapy.</li><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Any prior local therapy within 2 weeks of starting the study treatment.</li><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Presence of hepatic encephalopathy and/or clinically relevant ascites.</li><li style="margin: 0px; padding: 0px 0px 0px 20px; background-image: url(http://health.ucsd.edu/Style%20Library/Images/UCSD/bullet_body.gif); line-height: 18px; background-position: 0px 7px; background-repeat: no-repeat no-repeat;">Presence of main portal vein invasion by HCC.</li></ul></td></tr><tr id="ctl00_SPWebPartManager1_g_d1747a04_e80e_456a_b620_87654bcf82cd_ctl00_trLocation" style="margin: 0px; padding: 0px;"><td class="CT_Details_Left" style="margin: 0px; padding: 0px; font-family: verdana, arial, helvetica, sans-serif; vertical-align: top; color: rgb(45, 132, 175); width: 120px; font-weight: bold;">Study Location</td><td class="CT_Details_Right" style="margin: 0px; padding: 0px; font-size: 8pt; font-family: verdana, arial, helvetica, sans-serif; width: 400px;"><div style="margin: 0px; padding: 0px;"><span style="margin: 0px; padding: 0px; white-space: nowrap;">Moores UCSD Cancer Center</span><div style="margin: 0px; padding: 0px;">La Jolla, California, 92093</div></div></td></tr><tr style="margin: 0px; padding: 0px;"><td class="CT_Details_Left" style="margin: 0px; padding: 0px; font-family: verdana, arial, helvetica, sans-serif; vertical-align: top; color: rgb(45, 132, 175); width: 120px; font-weight: bold;">Contact</td><td class="CT_Details_Right" style="margin: 0px; padding: 0px; font-size: 8pt; font-family: verdana, arial, helvetica, sans-serif; width: 400px;"><span id="ctl00_SPWebPartManager1_g_d1747a04_e80e_456a_b620_87654bcf82cd_ctl00_lblContactName" style="margin: 0px; padding: 0px;">N/A</span></td></tr></tbody></table>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1382927600, 1364792400, 1397365200, 0),
	(1100, 1, 'Fatigue in Breast Cancer Survivors', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBreast Cancer\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCancer Survivor\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFatigue\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPsychosocial Effects of Cancer and Its Treatment\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspprotein analysis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsplaboratory biomarker analysis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspmass spectrometry\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspquestionnaire administration\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspassessment of therapy complications\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspcognitive assessment\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspquality-of-life assessment\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Fatigue in Breast Cancer Survivors', 1, 106, 0, 96, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Cancer Institute (NCI)</p><p>&nbsp&nbsp&nbspSt George\'s, University of London</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00972400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00972400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspCDR0000647658</p><p>&nbsp&nbsp&nbspSGUL-PTF-Mechanisms</p><p>&nbsp&nbsp&nbspEU-20958</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1413522000, 1230768000, 1382418000, 0),
	(1099, 1, 'Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspParents Who Have Lost a Child to Cancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspQuestionnaires/Interviews\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer', 1, 175, 0, 165, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Cohort</p><p>&nbsp&nbsp&nbspTime Perspective: Cross-Sectional</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspMemorial Sloan-Kettering Cancer Center</p><p>&nbsp&nbsp&nbspNational Cancer Institute (NCI)</p><p>&nbsp&nbsp&nbspDana Farber Cancer Institute/Harvard Medical School</p><p>&nbsp&nbsp&nbspOhio State University</p><p>&nbsp&nbsp&nbspUniversity of Memphis</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00968500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00968500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp09-107</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1428469200, 1249084800, 1397365200, 0),
	(1097, 1, 'Study of Tissue Samples From Patients With Glioma or Other Brain Tumors', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBrain and Central Nervous System Tumors\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsplaboratory biomarker analysis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsppharmacogenomic studies\n\r', 2, 0, 2, 'Y', 0.00, 0.00, 'Study of Tissue Samples From Patients With Glioma or Other Brain Tumors', 1, 160, 0, 150, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Cancer Institute (NCI)</p><p>&nbsp&nbsp&nbspUniversity Hospital, Montpellier</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00967200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00967200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspCDR0000626732</p><p>&nbsp&nbsp&nbspCHUM-DGS-2003/0402</p><p>&nbsp&nbsp&nbspCHUM-UF7745</p><p>&nbsp&nbsp&nbspINCA-RECF0467</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1430197200, 1067644800, 1399093200, 0),
	(1098, 1, 'Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspVariceal Bleeding\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCirrhosis\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEndoscopic band ligation\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPropranolol\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspendoscopic band ligation and propranolol\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding', 1, 298, 0, 288, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspKorea University</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00965900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00965900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspRCTPEBL</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1414126800, 1157068800, 1383022800, 0),
	(1096, 1, 'Bilateral Transversus Abdominis Plane Block and Postoperative Pain Intensity After Elective Cesarean Delivery', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPostoperative Pain\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTAP blockade\n\r', 2, 0, 2, 'Y', 0.00, 0.00, 'Bilateral Transversus Abdominis Plane Block and Postoperative Pain Intensity After Elective Cesarean Delivery', 1, 70, 0, 60, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Investigator)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspTehran University of Medical Sciences</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00964600</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00964600</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp825</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1411880400, 1220227200, 1380776400, 0),
	(1095, 1, 'Raltegravir Switch for Toxicity or Adverse Events', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHIV/AIDS\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAntiretroviral Therapy\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHIV Infections\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsptenofovir emtricitabine raltegravir\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspLamivudine Abacavir Raltegravir\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAbacavir free\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Raltegravir Switch for Toxicity or Adverse Events', 1, 50, 0, 40, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspCatholic University of the Sacred Heart</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00958100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00958100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2009â??014316â??35</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1431234000, 1249084800, 1400130000, 0),
	(1093, 1, 'Early Connections, Early Detection and Intervention in Infants at Risk for Autism', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAutism Spectrum Disorder\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAssessment &amp; Monitoring\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAssessment, Monitoring &amp; Intervention\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Early Connections, Early Detection and Intervention in Infants at Risk for Autism', 1, 210, 0, 200, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Washington</p><p>&nbsp&nbsp&nbspEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</p><p>&nbsp&nbsp&nbspNational Institute of Environmental Health Sciences (NIEHS)</p><p>&nbsp&nbsp&nbspAutism Speaks</p><p>&nbsp&nbsp&nbspWashington State Department of Social and Health Services</p><p>&nbsp&nbsp&nbspAutism Science Foundation</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00947700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00947700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp32400-G</p><p>&nbsp&nbsp&nbspNIH P50 HD055782</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1424408400, 1199145600, 1393304400, 0),
	(1094, 1, 'An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTemporomandibular Joint and Muscle Disorder\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBiobehavioral\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspActive Coping/Attention Intervention\n\r', 3, 0, 2, 'Y', 0.00, 0.00, 'An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)', 1, 685, 0, 675, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspThe University of Texas at Arlington</p><p>&nbsp&nbsp&nbspTexas A&amp;M University</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00952900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00952900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspU01 DE 010713</p><p>&nbsp&nbsp&nbspU01 DE 010713</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1431061200, 1217548800, 1399957200, 0),
	(1092, 1, 'Combined Haploidentical-Cord Blood Transplantation for Adults and Children', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspLeukemia\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMyelodysplastic Syndrome\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMultiple Myeloma\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspLymphoma\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFludarabine-Melphalan &amp; Rabbit antithymocyte globulin (r-ATG)\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspStem Cell Transplant\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspStem Cells Collections\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFludarabine, Busulfan, and ATG\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Combined Haploidentical-Cord Blood Transplantation for Adults and Children', 1, 110, 0, 100, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Chicago</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00943800</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00943800</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp14736B</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1422766800, 1159660800, 1391662800, 0),
	(1091, 1, 'Pharmacogenetic DNA Bank', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBlood collection\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Pharmacogenetic DNA Bank', 1, 5010, 0, 5000, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case-Crossover</p><p>&nbsp&nbsp&nbspTime Perspective: Cross-Sectional</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational University Hospital, Singapore</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00941200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00941200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspPG01/02/09</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1408683600, 1238544000, 1377579600, 0),
	(1090, 1, 'Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHypoxic Ischaemic Encephalopathy\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspXenon gas\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 3, 0, 2, 'Y', 0.00, 0.00, 'Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia', 1, 140, 0, 131, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspImperial College London</p><p>&nbsp&nbsp&nbspUniversity College London Hospitals</p><p>&nbsp&nbsp&nbspGuy\'s and St Thomas\' NHS Foundation Trust</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00934700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00934700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspprot-002-2009</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1431234000, 1328054400, 1400130000, 0),
	(1089, 1, 'A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCancer\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCataract\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspLow Bone Mineral Density\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspOsteopenia\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspOsteoporosis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspProstate Cancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDenosumab\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPlacebo\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for', 1, 770, 0, 760, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Supportive Care</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspAmgen</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspIndustry</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00925600</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00925600</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp20080560</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1420520400, 1257033600, 1389416400, 0),
	(1088, 1, 'The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAlcohol Drinking\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspD-cycloserine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPlacebo\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 3, 0, 2, 'Y', 0.00, 0.00, 'The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes', 1, 90, 0, 80, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Basic Science</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspCentral Institute of Mental Health, Mannheim</p><p>&nbsp&nbsp&nbspGerman Research Foundation</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00926900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00926900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspSFB636 D6 2006-007090-72</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1424494800, 1235865600, 1393390800, 0),
	(1087, 1, 'Study to Test the Usefulness of Magnetoencephalography (MEG) Imaging of Cognition in Children and Adolescents', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCognition\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Study to Test the Usefulness of Magnetoencephalography (MEG) Imaging of Cognition in Children and Adolescents', 1, 160, 0, 150, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case Control</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Nebraska</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00924300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00924300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp217-09-FB</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1427691600, 1246406400, 1396587600, 0),
	(1086, 1, 'Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHealthy\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspNalbuphine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMorphine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMorphine with Long dan xie gan tang\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspNalbuphine with Long dan xie gan tang\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspNubian with Long dan xie gan tang\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs', 1, 60, 0, 50, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Pharmacokinetics Study</p><p>&nbsp&nbsp&nbspIntervention Model: Crossover Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspTri-Service General Hospital</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00923000</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00923000</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspDDI-001</p><p>&nbsp&nbsp&nbspTSGHIRB096-02-015-A</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1428901200, 1228089600, 1397797200, 0),
	(1085, 1, 'Analgesic Effect of Paracetamol, Paracetamol + Codeine, Ibuprofen and Their Combination', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPain, Postoperative\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspIbuprofen + Paracetamol\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspIbuprofen + Paracetamol + Codeine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspParacetamol + Codeine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPlacebo\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 4, 0, 2, 'Y', 0.00, 0.00, 'Analgesic Effect of Paracetamol, Paracetamol + Codeine, Ibuprofen and Their Combination', 1, 210, 0, 200, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Pharmacodynamics Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUllevaal University Hospital</p><p>&nbsp&nbsp&nbspUniversity of Oslo</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00921700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00921700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspPARIBU-022</p><p>&nbsp&nbsp&nbspEUDRACT No. 2007-001778-10</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1423026000, 1243814400, 1391922000, 0),
	(1083, 1, 'Comparison of the HyperQ Versus Conventional Electrocardiogram (ECG) to Detect Ischemia', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCoronary Artery Disease\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Comparison of the HyperQ Versus Conventional Electrocardiogram (ECG) to Detect Ischemia', 1, 210, 0, 200, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case-Only</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspWest German Heart Center Essen</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00917800</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00917800</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspEssen 09-3981</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1411102800, 1241136000, 1379998800, 0),
	(1084, 1, 'N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDiabetic Nephropathies\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspProteinuria\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspOxidative Stress\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspN-acetylcysteine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspsilibin\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsphigh-dose silibin\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspN-acetylcysteine placebo\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspsilibin placebo\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy', 1, 235, 0, 225, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspThe University of Texas Health Science Center at San Antonio</p><p>&nbsp&nbsp&nbspNational Center for Complementary and Alternative Medicine (NCCAM)</p><p>&nbsp&nbsp&nbspDepartment of Veterans Affairs</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p><p>&nbsp&nbsp&nbspU.S. Fed</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00915200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00915200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspNIH 1R21AT004490-01A1</p><p>&nbsp&nbsp&nbsp1I01CX000264-01A2</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1408251600, 1254355200, 1377147600, 0),
	(1080, 1, 'Internet-based Intervention in Cardioverter-defibrillator Patients to Enhance Quality of Life', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHeart Diseases\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspImplantable Cardioverter-Defibrillators\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspweb-based multifactorial intervention\n\r', 4, 0, 2, 'Y', 0.00, 0.00, 'Internet-based Intervention in Cardioverter-defibrillator Patients to Enhance Quality of Life', 1, 360, 0, 350, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Tilburg</p><p>&nbsp&nbsp&nbspErasmus Medical Center</p><p>&nbsp&nbsp&nbspAmphia Hospital</p><p>&nbsp&nbsp&nbspCatharina Ziekenhuis Eindhoven</p><p>&nbsp&nbsp&nbspCanisius-Wilhelmina Hospital</p><p>&nbsp&nbsp&nbspOnze Lieve Vrouwe Gasthuis</p><p>&nbsp&nbsp&nbspVlietland ziekenhuis</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00895700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00895700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspUVT-MP-001</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1423371600, 1267401600, 1392267600, 0),
	(1081, 1, 'Prevalence of Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients With Biventricular (BiV) ', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHeart Failure\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Prevalence of Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients With Biventricular (BiV) ', 1, 60, 0, 50, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case-Only</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Texas Southwestern Medical Center</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00906100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00906100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspUTSW IRB 122007-040</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1408942800, 1209600000, 1377838800, 0),
	(1082, 1, 'Left Atrial Appendage Occlusion Study II', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAtrial Fibrillation\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspStroke\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSurgical occlusion of the left atrial appendage\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBest medical practice\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Left Atrial Appendage Occlusion Study II', 1, 60, 0, 50, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspPopulation Health Research Institute</p><p>&nbsp&nbsp&nbspCanadian Network for Clinical Trials Internationally (CANNeCTIN)</p><p>&nbsp&nbsp&nbspMcMaster University</p><p>&nbsp&nbsp&nbspUniversity of Toronto</p><p>&nbsp&nbsp&nbspUniversitÃ© de MontrÃ©al</p><p>&nbsp&nbsp&nbspUniversity of Ottawa Heart Institute</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00908700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00908700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspLAAOSII</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1406869200, 1249084800, 1375765200, 0),
	(1078, 1, 'Asthma Learning Project', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAsthma\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEducational game\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEducational game + motivational interview\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMotivational interview\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Asthma Learning Project', 1, 130, 0, 120, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspSeattle Children\'s Hospital</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00874900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00874900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspALP12526</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1407387600, 1228089600, 1375851600, 0),
	(1079, 1, 'Efficacy of Minoxidil in Children With Williams-Beuren Syndrome', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspWilliams Beuren Syndrome\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMinoxidil\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPlacebo\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Efficacy of Minoxidil in Children With Williams-Beuren Syndrome', 1, 70, 0, 60, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspHospices Civils de Lyon</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00876200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00876200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2006.437/30</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1422680400, 1235865600, 1391576400, 0),
	(1076, 1, 'Glucagon-Like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMetabolic Syndrome\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspGLP-1 infusion\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Glucagon-Like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome', 1, 30, 0, 20, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Rome Tor Vergata</p><p>&nbsp&nbsp&nbspMerck</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspIndustry</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00856700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00856700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp144/08</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1410843600, 1225497600, 1379739600, 0),
	(1077, 1, 'MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMyocardial Infarction\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBlood sample\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBlood sample\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction', 1, 810, 0, 800, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case Control</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspHospices Civils de Lyon</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00859300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00859300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2007.463</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1416027600, 1196467200, 1384923600, 0),
	(1075, 1, 'Proton Therapy for Hodgkin Lymphoma', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHodgkin Lymphoma\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspProton Radiation Plan\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspConventional Photon Radiation Plan\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspIntensity Modulated Radiation Plan\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Proton Therapy for Hodgkin Lymphoma', 1, 30, 0, 20, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Florida</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00850200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00850200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspUFPTI 0806 - HL01</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1411621200, 1249084800, 1380517200, 0),
	(1074, 1, 'Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhenylketonuria\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspKuvan\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response', 1, 30, 0, 20, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Miami</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00841100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00841100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp20080675</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1425704400, 1228089600, 1394600400, 0),
	(1073, 1, 'Children\'s Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAttention Deficit Disorder With Hyperactivity\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCATMH intervention\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Children\'s Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study', 1, 260, 0, 250, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Health Services Research</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspSeattle Children\'s Hospital</p><p>&nbsp&nbsp&nbspUniversity of Washington</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00830700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00830700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp12537</p><p>&nbsp&nbsp&nbspR01MH081997 NIMH</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1415163600, 1251763200, 1384059600, 0),
	(1072, 1, 'Cognitive Training to Enhance VA Work Program Outcomes', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMental Illness\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSchizophrenia\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDepression\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPTSD\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBipolar Disorder\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCognitive Remediation\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspNintendo Brain Age\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Cognitive Training to Enhance VA Work Program Outcomes', 1, 90, 0, 80, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspVA Connecticut Healthcare System</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspU.S. Fed</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00829400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00829400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspMDB0010-01101</p><p>&nbsp&nbsp&nbspD4752R</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1427000400, 1209600000, 1395896400, 0),
	(1071, 1, 'Progesterone for the Treatment of Traumatic Brain Injury', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTraumatic Brain Injury\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspProgesterone\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Progesterone for the Treatment of Traumatic Brain Injury', 1, 1150, 0, 1140, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspEmory University</p><p>&nbsp&nbsp&nbspDavid Wright</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00822900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00822900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspIRB00014409</p><p>&nbsp&nbsp&nbsp1RO1 NS062778-01</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1418360400, 1267401600, 1387256400, 0),
	(1070, 1, 'Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAcute Coronary Syndromes\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspIvabradine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPlacebo\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome', 1, 1280, 0, 1270, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Investigator)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspHospital Universitario de Canarias</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00815100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00815100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspRiviera/09</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1407819600, 1238544000, 1376715600, 0),
	(1068, 1, 'Community Based Exercise Program for Well Cancer Survivors', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspExercise program\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Community Based Exercise Program for Well Cancer Survivors', 1, 140, 0, 130, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Supportive Care</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspMcMaster University</p><p>&nbsp&nbsp&nbspHamilton Health Sciences Corporation</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00798200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00798200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspWorkForceOntario 001</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1420779600, 1235865600, 1389675600, 0),
	(1069, 1, 'Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellu', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHepatocellular Carcinoma\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCT-guided brachytherapy\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsptransarterial chemoembolization\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellu', 1, 78, 0, 68, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Crossover Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Magdeburg</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00807300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00807300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2005-000569-21</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1424667600, 1159660800, 1393563600, 0),
	(1067, 1, 'Bacterial Vaginosis in Pregnancy: Detection by Weekly Vaginal pH Testing', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPregnancy\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBacterial Vaginosis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPreterm Delivery\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspScreening\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Bacterial Vaginosis in Pregnancy: Detection by Weekly Vaginal pH Testing', 1, 3610, 0, 3600, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Crossover Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspHospital Clinic of Barcelona</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00799500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00799500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspFIS06/0559</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1418360400, 1167609600, 1387256400, 0),
	(1066, 1, 'An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment O', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHuman Immunodeficiency Virus (HIV)\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMaraviroc\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment O', 1, 135, 0, 125, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Pharmacokinetics Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspViiV Healthcare</p><p>&nbsp&nbsp&nbspPfizer</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspIndustry</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00791700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00791700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspA4001031</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1417064400, 1233446400, 1385960400, 0),
	(1065, 1, 'Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tum', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBrain and Central Nervous System Tumors\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChemotherapeutic Agent Toxicity\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCognitive/Functional Effects\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspNeurotoxicity\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPsychosocial Effects of Cancer and Its Treatment\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspRadiation Toxicity\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTherapy-related Toxicity\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspquestionnaire administration\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspcognitive assessment\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsppsychosocial assessment and care\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspquality-of-life assessment\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tum', 1, 765, 0, 755, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Cancer Institute (NCI)</p><p>&nbsp&nbsp&nbspChildren\'s Oncology Group</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00772200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00772200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspCDR0000594326</p><p>&nbsp&nbsp&nbspCOG-ALTE07C1</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1407387600, 1220227200, 1376283600, 0),
	(1061, 1, 'Ultrasound Evaluation of the Rotator Cable and Associated Structures.', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspShoulder Pain\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspultrasound\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspultrasound\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Ultrasound Evaluation of the Rotator Cable and Associated Structures.', 1, 40, 0, 30, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Diagnostic</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Michigan</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00743600</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00743600</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspHUM1500</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1418533200, 1125532800, 1387429200, 0),
	(1062, 1, 'A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspInguinal Hernia\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspRegional Anesthesia\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspGeneral Anesthesia\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and', 1, 730, 0, 720, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Bio-equivalence Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspChildren\'s Hospital Boston</p><p>&nbsp&nbsp&nbspRoyal Children\'s Hospital</p><p>&nbsp&nbsp&nbspRoyal Hospital for Sick Children</p><p>&nbsp&nbsp&nbspMurdoch Childrens Research Institute</p><p>&nbsp&nbsp&nbspFood and Drug Administration (FDA)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspU.S. Fed</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00756600</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00756600</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp06-07-0320</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1422853200, 1159660800, 1391749200, 0),
	(1063, 1, 'Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First A', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspInfluenza Type A\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspInfluenza Type B\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspNasopharyngeal Swab\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First A', 1, 16010, 0, 16000, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Ecologic or Community</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspSt. Jude Children\'s Research Hospital</p><p>&nbsp&nbsp&nbspThe University of Hong Kong</p><p>&nbsp&nbsp&nbspNational Institute of Allergy and Infectious Diseases (NIAID)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00760500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00760500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspSIVFRC</p><p>&nbsp&nbsp&nbspN01AI70005</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1421470800, 1072915200, 1390366800, 0),
	(1064, 1, 'Treatment for Word Retrieval Impairments in Aphasia', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspStroke\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspWord Retrieval Treatments for Aphasia\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Treatment for Word Retrieval Impairments in Aphasia', 1, 26, 0, 16, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Investigator)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspOld Dominion University</p><p>&nbsp&nbsp&nbspNational Institute on Deafness and Other Communication Disorders (NIDCD)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00764400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00764400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspR15 DC009690</p><p>&nbsp&nbsp&nbsp3R15DC009690</p><p>&nbsp&nbsp&nbspR15 DC009690</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1421989200, 1217548800, 1390885200, 0),
	(1060, 1, 'Cervical Stairstep and Effects on Range of Motion (ROM)', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspRange of Motion, Articular\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCervical Stairstep\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Cervical Stairstep and Effects on Range of Motion (ROM)', 1, 60, 0, 50, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspLogan College of Chiropractic</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00741000</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00741000</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspSR0331080127</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1428469200, 1214870400, 1397365200, 0),
	(1059, 1, 'Telephone Support for Dementia Caregivers', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDementia\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFamily Intervention:Telephone Tracking Support- Caregiver\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTelephone Support\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Telephone Support for Dementia Caregivers', 1, 284, 0, 274, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Supportive Care</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspRhode Island Hospital</p><p>&nbsp&nbsp&nbspNational Institute of Nursing Research (NINR)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00735800</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00735800</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspR01NR010559</p><p>&nbsp&nbsp&nbspR01NR010559</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1411275600, 1201824000, 1378357200, 0),
	(1058, 1, 'Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCognitive Dysfunction\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction', 1, 110, 0, 100, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case-Only</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Taiwan University Hospital</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00731900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00731900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp9561707009</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1422075600, 1175385600, 1390971600, 0),
	(1056, 1, 'High Density Lipoprotein (HDL) Functionality in Metabolic Syndrome', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMetabolic Syndrome X\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'High Density Lipoprotein (HDL) Functionality in Metabolic Syndrome', 1, 40, 0, 30, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case Control</p><p>&nbsp&nbsp&nbspTime Perspective: Cross-Sectional</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspThe University of Western Australia</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00716300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00716300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspDC-HDL2008</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1413781200, 1214870400, 1382677200, 0),
	(1057, 1, 'ICU Family Communication Study', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDepression\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDepressive Symptoms\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAnxiety\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspStress Disorders, Post-Traumatic\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspICU Hospitalization\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCare and Treatment in ICU\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFacilitator-Based intervention\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspUsual Care\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'ICU Family Communication Study', 1, 6510, 0, 6500, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Supportive Care</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Washington</p><p>&nbsp&nbsp&nbspNational Institute of Nursing Research (NINR)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00720200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00720200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp33587-C</p><p>&nbsp&nbsp&nbsp2R01NR005226</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1418014800, 1212278400, 1386910800, 0),
	(1055, 1, 'Oral Versus Intravenous Rehydration for Prevention of Dehydration in Premature Babies, During the First Days of Life.', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspLow Birth Weight Infant\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEnteral Nutrition\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspOral rehydration therapy\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspclassical hydration via intravenous infusion\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Oral Versus Intravenous Rehydration for Prevention of Dehydration in Premature Babies, During the First Days of Life.', 1, 360, 0, 350, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspAssistance Publique - HÃ´pitaux de Paris</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00715000</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00715000</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspP060208</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1408165200, 1214870400, 1377061200, 0),
	(1054, 1, 'Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTobacco Use Disorder\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspProduct Preference\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers', 1, 160, 0, 150, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institute on Drug Abuse (NIDA)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00711100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00711100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp1R01 CA135884</p><p>&nbsp&nbsp&nbspStudy 1</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1412398800, 1217548800, 1381294800, 0),
	(1053, 1, 'Varenicline to Reduce Alcohol Consumption in Heavy Drinkers', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAlcohol Drinking\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspVarenicline\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspVarenicline (Chantix)\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Varenicline to Reduce Alcohol Consumption in Heavy Drinkers', 1, 190, 0, 180, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double-Blind</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institutes of Health Clinical Center (CC)</p><p>&nbsp&nbsp&nbspNational Institute on Alcohol Abuse and Alcoholism (NIAAA)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00695500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00695500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp080137</p><p>&nbsp&nbsp&nbsp08-AA-0137</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1409461200, 1212278400, 1378357200, 0),
	(1052, 1, 'Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPancreas Neoplasms\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDocetaxel\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspOxaliplatin\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer', 1, 54, 0, 44, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Ulm</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00690300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00690300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspI1-GOA-1</p><p>&nbsp&nbsp&nbspEudraCT 2005-004236-40</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1415077200, 1199145600, 1383973200, 0),
	(1051, 1, 'Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspOvarian Cancer\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPeritoneal Cancer\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFallopian Tube Cancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspintravenous docetaxel with intraperitoneal oxaliplatin\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspintravenous oxaliplatin with intraperitoneal docetaxel\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer', 1, 50, 0, 40, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Pittsburgh</p><p>&nbsp&nbsp&nbspSanofi</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspIndustry</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00692900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00692900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspOX-06-009</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1409029200, 1228089600, 1376888400, 0),
	(1049, 1, 'Platelet Function Testing Help and Intraoperative Bleeding Risk for Patients Who Are on Plavix Prior to Surgery', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPerioperative Bleeding\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Platelet Function Testing Help and Intraoperative Bleeding Risk for Patients Who Are on Plavix Prior to Surgery', 1, 30, 0, 20, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Cohort</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspCedars-Sinai Medical Center</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00653900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00653900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspPro00013820</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1420520400, 1207008000, 1389416400, 0),
	(1050, 1, 'A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSchizophrenia\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSchizophreniform Disorder\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSchizoaffective Disorder\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTAU = treatment as usual\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia', 1, 370, 0, 360, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case Control</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspMartin-Luther-UniversitÃ¤t Halle-Wittenberg</p><p>&nbsp&nbsp&nbspUniversity of Heidelberg</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00686400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00686400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp07R-1815, SMRI</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1424494800, 1209600000, 1393390800, 0),
	(1048, 1, 'Ziprasidone in the Psychosis Prodrome', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPsychosis Prodrome\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspziprasidone\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspplacebo\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Ziprasidone in the Psychosis Prodrome', 1, 90, 0, 80, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspYale University</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00635700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00635700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp0801003386</p><p>&nbsp&nbsp&nbspIIR GA1281GE</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1413176400, 1204329600, 1382072400, 0),
	(1047, 1, 'Effect of Large Volume Paracentesis on Fatigue in Cirrhosis', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAscites\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFatigue\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCirrhosis\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Effect of Large Volume Paracentesis on Fatigue in Cirrhosis', 1, 20, 0, 10, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case-Only</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspWeill Medical College of Cornell University</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00603200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00603200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp0701008974</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1423630800, 1199145600, 1392526800, 0),
	(1046, 1, 'Capsule Endoscopy Crohn\'s Disease Activity Index - Validation Multi Center Study', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCrohn\'s Disease\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspGivenÂ® Diagnostic System including PillCamTM SB Capsules\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Capsule Endoscopy Crohn\'s Disease Activity Index - Validation Multi Center Study', 1, 110, 0, 100, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Diagnostic</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspRabin Medical Center</p><p>&nbsp&nbsp&nbspDepartment of Veterans Affairs</p><p>&nbsp&nbsp&nbspRambam Health Care Campus</p><p>&nbsp&nbsp&nbspAssaf-Harofeh Medical Center</p><p>&nbsp&nbsp&nbspHillel Yaffe Medical Center</p><p>&nbsp&nbsp&nbspUniversity of Athens</p><p>&nbsp&nbsp&nbspUniversity of Magdeburg</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspU.S. Fed</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00596700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00596700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspCECDAI-2006</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1431406800, 1167609600, 1400302800, 0),
	(1045, 1, 'Safety of Driving After Minor Surgery With Monitored Anesthesia Care', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMinor Surgical Procedures With Monitored Anesthesia Care.\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDriving Performance After Minor Ambulatory Surgery.\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMidazolam\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSufentanil\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPropofol\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Safety of Driving After Minor Surgery With Monitored Anesthesia Care', 1, 635, 0, 625, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspRush University Medical Center</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00577200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00577200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspABuv110507</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1422507600, 1199145600, 1391403600, 0),
	(1044, 1, 'Fertility Preservation by Ovarian and Oocyte Cryopreservation', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale Patients Aged 5-35 Prior to Systemic Chemotherapy\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspWith Significant Risk of Ovarian Toxicity\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspovarian transplantation\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Fertility Preservation by Ovarian and Oocyte Cryopreservation', 1, 210, 0, 200, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspHadassah Medical Organization</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00578500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00578500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2819</p><p>&nbsp&nbsp&nbsp29-18/1/08</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1409288400, 946684800, 1378184400, 0),
	(1043, 1, 'Safety Study of GlaxoSmithKline (GSK) Biologicals\' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to ', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHuman Papillomavirus (HPV) Vaccine\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHPV-16/18 L1 VLP AS04 vaccine\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Safety Study of GlaxoSmithKline (GSK) Biologicals\' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to ', 1, 232, 0, 222, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institute for Control of Vaccine and Biologicals</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00572000</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00572000</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp111040 (HPV-022 PRI)</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1432270800, 1193875200, 1401166800, 0),
	(1042, 1, 'Erlotinib in Treating Patients With Barrett Esophagus', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEsophageal Cancer\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPrecancerous Condition\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsperlotinib hydrochloride\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsplaboratory biomarker analysis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspbiopsy\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Erlotinib in Treating Patients With Barrett Esophagus', 1, 35, 0, 25, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Cancer Institute (NCI)</p><p>&nbsp&nbsp&nbspKansas City Veteran Affairs Medical Center</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspU.S. Fed</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00566800</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00566800</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspCDR0000576425</p><p>&nbsp&nbsp&nbspVAMCK-JB0027</p><p>&nbsp&nbsp&nbspGENENTECH-OSI3717s</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1423544400, 1183248000, 1392440400, 0),
	(1041, 1, 'MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Pr', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMultiple Myeloma\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBortezomib\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspdexamethasone\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFludarabine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMelphalan\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Pr', 1, 40, 0, 30, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspPETHEMA Foundation</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00564200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00564200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2005-004858-27</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1432184400, 1193875200, 1401080400, 0),
	(1038, 1, 'Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Brain Injury.', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCraniocerebral Trauma\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTraumatic Brain Injury\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSubarachnoid Hemorrhage\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAnoxic Brain Injury\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTilt Table With Integrated Stepping System\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 0\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Brain Injury.', 1, 70, 0, 60, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Aarhus</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00526500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00526500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspHNRC-AAU-07-1</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1425186000, 1154390400, 1394082000, 0),
	(1039, 1, 'Effects of Bariatric Surgery on Insulin', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspObesity\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBariatric Surgery\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspGastric Bypass\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspWeight Loss\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHyperglycemia\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Effects of Bariatric Surgery on Insulin', 1, 82, 0, 72, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institutes of Health Clinical Center (CC)</p><p>&nbsp&nbsp&nbspNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00535600</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00535600</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp999907226</p><p>&nbsp&nbsp&nbsp07-DK-N226</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1423026000, 1188604800, 1391922000, 0),
	(1040, 1, 'Chronic Obstructive Pulmonary Disease (COPD) Nutrition Support Trial', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMalnutrition\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspOral Nutritional Supplements (Fortisip)\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDietary Advice\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Chronic Obstructive Pulmonary Disease (COPD) Nutrition Support Trial', 1, 210, 0, 200, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Southampton</p><p>&nbsp&nbsp&nbspUniversity Hospital Southampton NHS Foundation Trust.</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00538200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00538200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspELIA002</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1411621200, 1199145600, 1380517200, 0),
	(1036, 1, 'Postoperative Cognitive Dysfunction in Geriatric Patients', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDelirium, Dementia, Amnestic, Cognitive Disorders\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAge\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPostoperative Complications\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMemory Disorders\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Postoperative Cognitive Dysfunction in Geriatric Patients', 1, 310, 0, 300, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Cohort</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity Hospital, Basel, Switzerland</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00512200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00512200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspEK 75/07</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1422853200, 1183248000, 1391749200, 0),
	(1037, 1, 'Home Blood Pressure Monitoring Trial', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspStroke\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspIschemic Attack, Transient\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspIntervention - a validated home BP monitor and support from the specialist nurse\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspControl - usual care (BP monitoring by their practice)\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Home Blood Pressure Monitoring Trial', 1, 370, 0, 360, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspSt George\'s, University of London</p><p>&nbsp&nbsp&nbspThe Stroke Association, United Kingdom</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00514800</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00514800</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp07.0002</p><p>&nbsp&nbsp&nbspTSA 2006/05</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1420952400, 1172707200, 1389848400, 0),
	(1035, 1, 'Epidural Analgesia (EDA) Versus Patient Controlled Analgesia (PCA) in Laparoscopic Colon Surgery', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspLaparoscopic Colectomy\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEpidural analgesia\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPatient controlled analgesia\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Epidural Analgesia (EDA) Versus Patient Controlled Analgesia (PCA) in Laparoscopic Colon Surgery', 1, 138, 0, 129, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Lausanne Hospitals</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00508300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00508300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspP166/07</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1428814800, 1262304000, 1397710800, 0),
	(1034, 1, 'Somatosensory Evoked Potentials and Pain Thresholds in Term and Preterm-Born Adolescents After Early Exposure to Pain; a Quantit', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSomatosensory Disorders\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspThermal stimulation\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Somatosensory Evoked Potentials and Pain Thresholds in Term and Preterm-Born Adolescents After Early Exposure to Pain; a Quantit', 1, 90, 0, 80, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case Control</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspSoroka University Medical Center</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00503100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00503100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspSOR458107CTIL</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1431666000, 1185926400, 1400562000, 0),
	(1033, 1, 'Collection of Samples and Data for the National Marrow Donor Program Repository', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHematopoietic Stem Cell Transplantation\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Collection of Samples and Data for the National Marrow Donor Program Repository', 1, 510, 0, 500, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institutes of Health Clinical Center (CC)</p><p>&nbsp&nbsp&nbspNational Institute of Allergy and Infectious Diseases (NIAID)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00495300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00495300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp070183</p><p>&nbsp&nbsp&nbsp07-I-0183</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1416200400, 1180656000, 1385096400, 0),
	(1031, 1, 'Inflammatory Breast Cancer (IBC) Registry', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBreast Cancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspInterview\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBlood and Tissue Collection\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Inflammatory Breast Cancer (IBC) Registry', 1, 510, 0, 500, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case Control</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspM.D. Anderson Cancer Center</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00477100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00477100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2006-1072</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1432098000, 1175385600, 1400994000, 0),
	(1032, 1, 'Awareness of Deficit After Combat-related Brain Injury', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTraumatic Brain Injury\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspVeterans\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Awareness of Deficit After Combat-related Brain Injury', 1, 110, 0, 100, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Case Control</p><p>&nbsp&nbsp&nbspTime Perspective: Cross-Sectional</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Wisconsin, Madison</p><p>&nbsp&nbsp&nbspDepartment of Veterans Affairs</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspU.S. Fed</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00478400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00478400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2006-0256</p><p>&nbsp&nbsp&nbsp2006-0256</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1412658000, 1191196800, 1381554000, 0),
	(1030, 1, 'Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHyperhomocysteinemia\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspS-adenosylmethionine\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine', 1, 110, 0, 100, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Investigator)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Basic Science</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspBaylor Research Institute</p><p>&nbsp&nbsp&nbspNational Institutes of Health (NIH)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00473200</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00473200</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspBaylor IRB #005-210</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1415250000, 1249084800, 1384146000, 0),
	(1028, 1, 'Pharmacokinetic of Ceftriaxone in Septic ICU Patients', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSepsis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSevere Sepsis\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSeptic Shock\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspceftriaxone\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Pharmacokinetic of Ceftriaxone in Septic ICU Patients', 1, 80, 0, 70, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Pharmacokinetics/Dynamics Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspAssociation Pour La Promotion A Tours De La Reanimation Medicale</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00449800</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00449800</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspAPTRM 2006-02</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1428382800, 1151712000, 1397278800, 0),
	(1029, 1, 'Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChagas Disease\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTrypanosoma cruzi serology\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram', 1, 310, 0, 300, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Screening</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of California, Los Angeles</p><p>&nbsp&nbsp&nbspCenters for Disease Control and Prevention</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspU.S. Fed</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00453700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00453700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp06H-561004</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1414386000, 1170288000, 1383282000, 0),
	(1027, 1, 'Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAnxiety\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMechanical Ventilation\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspRespiratory Conditions Such as Pneumonia or COPD\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAnxiety Self-Management, Patient preferred relaxing music\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspControl 1: Noise-cancelling headphones\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspControl 2: Usual Care\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation', 1, 196, 0, 186, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Minnesota - Clinical and Translational Science Institute</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00440700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00440700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp0601M79066</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1413262800, 1151712000, 1382158800, 0),
	(1026, 1, 'Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMultiple Sclerosis\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis', 1, 74, 0, 64, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institutes of Health Clinical Center (CC)</p><p>&nbsp&nbsp&nbspNational Institute of Neurological Disorders and Stroke (NINDS)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00432900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00432900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp070092</p><p>&nbsp&nbsp&nbsp07-N-0092</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1410325200, 1170288000, 1379221200, 0),
	(1025, 1, 'Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPolycystic Ovary Syndrome\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspclomiphene citrate\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspraloxifene\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 3\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome', 1, 90, 0, 80, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspHospital de Clinicas de Porto Alegre</p><p>&nbsp&nbsp&nbspGreenville Hospital Center of Women\'s Medicine</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00427700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00427700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspRACLO</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1417842000, 1217548800, 1386738000, 0),
	(1024, 1, 'Anti-Aggregative Therapy and Laser Iridectomy', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEyes With Narrow Angle\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspThe cessation of anti-aggregative treatment for 10 days\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 4\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Anti-Aggregative Therapy and Laser Iridectomy', 1, 10, 0, 0, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspSheba Medical Center</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00426400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00426400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspSHEBA-05-3876-HLV-CTIL</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1429938000, 1141171200, 1398834000, 0),
	(1021, 1, 'Mechanism and Prevention of Remote Organ Injury Following Ruptured Aortic Aneurysm', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAbdominal Aortic Aneurysm\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Mechanism and Prevention of Remote Organ Injury Following Ruptured Aortic Aneurysm', 1, 70, 0, 60, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Defined Population</p><p>&nbsp&nbsp&nbspPrimary Purpose: Screening</p><p>&nbsp&nbsp&nbspTime Perspective: Cross-Sectional</p><p>&nbsp&nbsp&nbspTime Perspective: Retrospective/Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity Health Network, Toronto</p><p>&nbsp&nbsp&nbspThe Physicians\' Services Incorporated Foundation</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00416000</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00416000</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp06-0671B</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1421730000, 1136073600, 1390626000, 0),
	(1022, 1, 'Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPost-Traumatic Stress Disorder\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspProlonged exposure (PE) therapy for adolescents\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspClient centered therapy (CCT)\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse', 1, 100, 0, 90, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Outcomes Assessor)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institute of Mental Health (NIMH)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00417300</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00417300</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspR01 MH074505</p><p>&nbsp&nbsp&nbspDSIR CT-C</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1408683600, 1167609600, 1377579600, 0),
	(1023, 1, 'Use of Hair to Diagnose the Presence of Breast Cancer', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBreast Cancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspdiagnosis of breast cancer by x-ray diffraction of hair\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 1\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Use of Hair to Diagnose the Presence of Breast Cancer', 1, 2010, 0, 2000, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind</p><p>&nbsp&nbsp&nbspPrimary Purpose: Screening</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspFermiscan Ltd</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspIndustry</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00419900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00419900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspFER2k</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1420002000, 1164931200, 1388898000, 0),
	(1020, 1, 'Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMelanoma\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspRadiotherapy\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMetastatic Disease\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspTreatment of metastatic disease\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma', 1, 570, 0, 560, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Defined Population</p><p>&nbsp&nbsp&nbspPrimary Purpose: Screening</p><p>&nbsp&nbsp&nbspTime Perspective: Longitudinal</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspLudwig-Maximilians - University of Munich</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00406900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00406900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspMIA</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1413608400, 915148800, 1382504400, 0),
	(1019, 1, 'Is it Possible to Treat Cyanide Poisoning With HBO?', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCarbon Monoxide Poisoning From Fire Accidents\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHBO - hyperbaric oxygen treatment\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Is it Possible to Treat Cyanide Poisoning With HBO?', 1, 10, 0, 0, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Defined Population</p><p>&nbsp&nbsp&nbspTime Perspective: Longitudinal</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspRigshospitalet, Denmark</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00399100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00399100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp01-277/99</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1421298000, 1162339200, 1390194000, 0),
	(1017, 1, 'A Phase II Study of Tegafur/Uracil (UFURÂ®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCarcinoma, Hepatocellular\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspThalidomide(THADO), Tegafur/Uracil(UFUR)\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'A Phase II Study of Tegafur/Uracil (UFURÂ®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma', 1, 51, 0, 41, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspFar Eastern Memorial Hospital</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00384800</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00384800</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspFEMH-94037</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1426136400, 1157068800, 1395032400, 0),
	(1018, 1, 'Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspLymphedema\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBreast Cancer\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFlexitouch\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status', 1, 210, 0, 200, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Single Blind (Subject)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspStanford University</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00383500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00383500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspBRSNSTU0007</p><p>&nbsp&nbsp&nbsp95970</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1417582800, 1114905600, 1386478800, 0),
	(1015, 1, 'Treatment of Non-Dislocated Midshaft Both-Bone Fractures', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFracture\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspabove and below elbow cast\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Treatment of Non-Dislocated Midshaft Both-Bone Fractures', 1, 70, 0, 60, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Crossover Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspColaris, Joost, M.D.</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00314600</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00314600</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspColaris02</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1417669200, 1136073600, 1386565200, 0),
	(1016, 1, 'Measurement of Stress During Anesthesia With &quot;Pain Detector&quot; on Patients Receiving Atropine', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHemorrhoids\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFissure in Ano\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdministration of 0,7 mg of atropine\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMeasurement of skin conductance with Pain detector\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Measurement of Stress During Anesthesia With &quot;Pain Detector&quot; on Patients Receiving Atropine', 1, 34, 0, 24, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Factorial Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspRikshospitalet University Hospital</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00328900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00328900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspS-03113</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1424667600, 1136073600, 1393563600, 0),
	(1014, 1, 'Treatment of Subarachnoid Hemorrhage With Human Albumin', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSubarachnoid Hemorrhage\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsphuman albumin\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Treatment of Subarachnoid Hemorrhage With Human Albumin', 1, 90, 0, 80, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspBaylor College of Medicine</p><p>&nbsp&nbsp&nbspNational Institute of Neurological Disorders and Stroke (NINDS)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00283400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00283400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspR01NS049135</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1428296400, 1136073600, 1397192400, 0),
	(1013, 1, 'The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHealthy\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspGLP-2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans', 1, 20, 0, 10, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Non-Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Pharmacokinetics/Dynamics Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Health Services Research</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspGlostrup University Hospital, Copenhagen</p><p>&nbsp&nbsp&nbspRigshospitalet, Denmark</p><p>&nbsp&nbsp&nbspUniversity of Copenhagen</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00273000</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00273000</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspGLP-2, MBF</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1409202000, 1136073600, 1378098000, 0),
	(1012, 1, 'Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPatients Requiring Haemofiltration for Acute Renal Failure.\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFondaparinux Sodium\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.', 1, 30, 0, 20, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspMelbourne Health</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00256100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00256100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp2004.066</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1421989200, 1086048000, 1390885200, 0),
	(1001, 1, 'Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspHIV Infections\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCachexia\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsptestosterone\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women', 1, 66, 0, 56, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspMasking: Double-Blind</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspFDA Office of Orphan Products Development</p><p>&nbsp&nbsp&nbspCharles Drew University of Medicine and Science</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspU.S. Fed</p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00004400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00004400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp199/13251</p><p>&nbsp&nbsp&nbspCDUMS-FDR001397</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1412485200, 859852800, 1381381200, 0),
	(1002, 1, 'Measurement of Outcome of Surgical Treatment in Patients With Acromegaly', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAcromegaly\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Measurement of Outcome of Surgical Treatment in Patients With Acromegaly', 1, 175, 0, 165, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspPrimary Purpose: Screening</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Center for Research Resources (NCRR)</p><p>&nbsp&nbsp&nbspColumbia University</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00005100</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00005100</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspNCRR-M01RR00645-2525</p><p>&nbsp&nbsp&nbspCPMC-IRB-7590</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1426222800, 936144000, 1395118800, 0),
	(1011, 1, 'Pompe Disease Registry', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspGlycogen Storage Disease Type II\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPompe Disease\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Pompe Disease Registry', 1, 2010, 0, 2000, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Cohort</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspGenzyme</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspIndustry</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00231400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00231400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspPompe Registry Protocol</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1418792400, 1093996800, 1387688400, 0),
	(1003, 1, 'Stachybotrys Induced Hemorrhage in the Developing Lung', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspIdiopathic Pulmonary Hemorrhage\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Stachybotrys Induced Hemorrhage in the Developing Lung', 1, 60, 0, 50, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAdditional Descriptors: Convenience Sample</p><p>&nbsp&nbsp&nbspObservational Model: Natural History</p><p>&nbsp&nbsp&nbspTime Perspective: Longitudinal</p><p>&nbsp&nbsp&nbspTime Perspective: Retrospective/Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Institute of Environmental Health Sciences (NIEHS)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00011700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00011700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp9742-CP-001</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1421384400, 915148800, 1390280400, 0),
	(1004, 1, 'Human Epilepsy Genetics--Neuronal Migration Disorders Study', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEpilepsy\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSeizures\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspCognition Disorders\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspNeuronal Migration Disorders\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspChild\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Human Epilepsy Genetics--Neuronal Migration Disorders Study', 1, 3510, 0, 3500, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Family-Based</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspHarvard University Faculty of Medicine</p><p>&nbsp&nbsp&nbspNational Institute of Neurological Disorders and Stroke (NINDS)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00041600</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00041600</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspR01NS35129</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1414990800, 828316800, 1383886800, 0),
	(1005, 1, 'Familial Amyotrophic Lateral Sclerosis (FALS) Study', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAmyotrophic Lateral Sclerosis\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Familial Amyotrophic Lateral Sclerosis (FALS) Study', 1, 10010, 0, 10000, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Cohort</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Miami</p><p>&nbsp&nbsp&nbspMichael Benatar</p><p>&nbsp&nbsp&nbspALS Association</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00136500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00136500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspFALS feasibility</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1414558800, 1107216000, 1383454800, 0),
	(1006, 1, 'MRS and DTI of White Matter in Alzheimer\'s Disease', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAlzheimer\'s Disease\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspVascular Dementia\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'MRS and DTI of White Matter in Alzheimer\'s Disease', 1, 50, 0, 40, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspObservational Model: Defined Population</p><p>&nbsp&nbsp&nbspObservational Model: Natural History</p><p>&nbsp&nbsp&nbspTime Perspective: Cross-Sectional</p><p>&nbsp&nbsp&nbspTime Perspective: Prospective</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspNational Taiwan University Hospital</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00172900</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00172900</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp9461700320</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1427950800, 1117584000, 1396846800, 0),
	(1007, 1, 'Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAllergic Disease\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspObesity\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspImmunology\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspFemale\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDietary counselling and placebo\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspDietary counselling and probiotics\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPlacebo capsules\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspProbiotics\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPrebiotics\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight', 1, 810, 0, 800, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Safety/Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double Blind (Subject, Caregiver, Investigator)</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity of Turku</p><p>&nbsp&nbsp&nbspAcademy of Finland</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00167700</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00167700</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp15214</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1416891600, 854755200, 1385787600, 0),
	(1008, 1, 'Efficacy of Modified Ketogenic Diet (Atkins) in Management of Epilepsy', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspEpilepsy\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSenior\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspatkins diet\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspability to follow low carbohydrate diet\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Efficacy of Modified Ketogenic Diet (Atkins) in Management of Epilepsy', 1, 10, 0, 0, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Open Label</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspUniversity Health Network, Toronto</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00188500</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00188500</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbsp05-0027-AE</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1422421200, 1122854400, 1391317200, 0),
	(1009, 1, 'A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&quot;Hyperuricemia,Anserine&quot;\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMarine active\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.', 1, 10, 0, 0, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Parallel Assignment</p><p>&nbsp&nbsp&nbspMasking: Double-Blind</p><p>&nbsp&nbsp&nbspPrimary Purpose: Treatment</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspChina Medical University Hospital</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00208000</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00208000</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspDMR93-IRB-22</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1411794000, 1088640000, 1380690000, 0),
	(1010, 1, 'Brief Intervention to Reduce STDs in ER Drug Users - 1', 'Conditions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSubstance-Related Disorders\n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspSexual Risk Behaviors\n\rGender: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspBoth\n\rAge groups: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspAdult\n\rInterventions: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspMotivational interviewing\n\rPhases: \n\r&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp&nbspPhase 2\n\r', 0, 0, 2, 'Y', 0.00, 0.00, 'Brief Intervention to Reduce STDs in ER Drug Users - 1', 1, 3350, 0, 3340, 'team/2013/0403/13650073238645.png', NULL, NULL, '', '', 0, 0, 5, '', '<p><b>Study designs:</b></p><p>&nbsp&nbsp&nbspAllocation: Randomized</p><p>&nbsp&nbsp&nbspEndpoint Classification: Efficacy Study</p><p>&nbsp&nbsp&nbspIntervention Model: Single Group Assignment</p><p>&nbsp&nbsp&nbspMasking: Double-Blind</p><p>&nbsp&nbsp&nbspPrimary Purpose: Prevention</p>', '<p><b>Sponsers:</b></p><p>&nbsp&nbsp&nbspBoston Medical Center</p><p>&nbsp&nbsp&nbspNational Institute on Drug Abuse (NIDA)</p><p><b>Funded by:</b></p><p>&nbsp&nbsp&nbspOther</p><p>&nbsp&nbsp&nbspNIH</p>', '', '<p><b>Link:</b></p><p>&nbsp&nbsp&nbsphttp://ClinicalTrials.gov/show/NCT00218400</p><p><b>NCT ID:</b></p><p>&nbsp&nbsp&nbspNCT00218400</p><p><b>Other IDs:</b></p><p>&nbsp&nbsp&nbspNIDA-17061-1</p><p>&nbsp&nbsp&nbspR01DA017061</p><p>&nbsp&nbsp&nbspR01-17061-1</p>', '', 'coupon', 'none', 'N', 'Y', 'normal', 1423976400, 1101859200, 1392872400, 0);
/*!40000 ALTER TABLE `team` ENABLE KEYS */;


-- Dumping structure for table rct.topic
DROP TABLE IF EXISTS `topic`;
CREATE TABLE IF NOT EXISTS `topic` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `parent_id` int(10) unsigned NOT NULL DEFAULT '0',
  `user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `title` varchar(128) DEFAULT NULL,
  `team_id` int(10) unsigned NOT NULL DEFAULT '0',
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `public_id` int(10) unsigned NOT NULL DEFAULT '0',
  `content` text,
  `head` int(10) unsigned NOT NULL DEFAULT '0',
  `reply_number` int(10) unsigned NOT NULL DEFAULT '0',
  `view_number` int(10) unsigned NOT NULL DEFAULT '0',
  `last_user_id` int(10) unsigned NOT NULL DEFAULT '0',
  `last_time` int(10) unsigned NOT NULL DEFAULT '0',
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Dumping data for table rct.topic: 0 rows
DELETE FROM `topic`;
/*!40000 ALTER TABLE `topic` DISABLE KEYS */;
/*!40000 ALTER TABLE `topic` ENABLE KEYS */;


-- Dumping structure for table rct.user
DROP TABLE IF EXISTS `user`;
CREATE TABLE IF NOT EXISTS `user` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `email` varchar(128) DEFAULT NULL,
  `username` varchar(32) DEFAULT NULL,
  `realname` varchar(32) DEFAULT NULL,
  `password` varchar(32) DEFAULT NULL,
  `avatar` varchar(128) DEFAULT NULL,
  `gender` enum('M','F') NOT NULL DEFAULT 'M',
  `newbie` enum('Y','N') NOT NULL DEFAULT 'Y',
  `mobile` varchar(16) DEFAULT NULL,
  `qq` varchar(16) DEFAULT NULL,
  `money` double(10,2) NOT NULL DEFAULT '0.00',
  `zipcode` char(6) DEFAULT NULL,
  `address` varchar(255) DEFAULT NULL,
  `city_id` int(10) unsigned NOT NULL DEFAULT '0',
  `enable` enum('Y','N') NOT NULL DEFAULT 'Y',
  `manager` enum('Y','N') NOT NULL DEFAULT 'N',
  `secret` varchar(32) DEFAULT NULL,
  `recode` varchar(32) DEFAULT NULL,
  `ip` varchar(16) DEFAULT NULL,
  `login_time` int(10) unsigned NOT NULL DEFAULT '0',
  `create_time` int(10) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id`),
  UNIQUE KEY `UNQ_name` (`username`),
  UNIQUE KEY `UNQ_e` (`email`)
) ENGINE=MyISAM AUTO_INCREMENT=13 DEFAULT CHARSET=utf8;

-- Dumping data for table rct.user: 12 rows
DELETE FROM `user`;
/*!40000 ALTER TABLE `user` DISABLE KEYS */;
INSERT INTO `user` (`id`, `email`, `username`, `realname`, `password`, `avatar`, `gender`, `newbie`, `mobile`, `qq`, `money`, `zipcode`, `address`, `city_id`, `enable`, `manager`, `secret`, `recode`, `ip`, `login_time`, `create_time`) VALUES
	(1, 'xiaoqian.jiang@gmail.com', 'xiaoqianjiang', NULL, 'b68143cb4fa344977dd8b386a69fc98b', NULL, 'M', 'Y', '4127364200', NULL, 0.00, NULL, NULL, 0, 'Y', 'Y', '', NULL, '127.0.0.1', 1364957270, 1364957270),
	(2, 'wsasyz@hotmail.com', 'wsasyz', NULL, 'e7fe8b88db51d86ef2f5e169144b9c1b', NULL, 'M', 'Y', '9188108103092', NULL, 0.00, NULL, NULL, 4, 'Y', 'Y', '94a68136942793204c5a4ae35a6c0a66', NULL, '98.155.79.207', 1365482323, 1365482323),
	(3, 'lj.cui@hotmail.com', 'wsasyz002', NULL, 'e7fe8b88db51d86ef2f5e169144b9c1b', NULL, 'M', 'Y', '9182849782', NULL, 0.00, NULL, NULL, 3, 'Y', 'Y', '7a1e04c2221bdeffdf409258e8c79506', NULL, '132.239.245.147', 1365698621, 1365698621),
	(4, 'wsasyz003@hotmail.com', 'wsasyz003', NULL, 'e7fe8b88db51d86ef2f5e169144b9c1b', NULL, 'M', 'Y', '9182849782', NULL, 0.00, NULL, NULL, 3, 'Y', 'Y', '401931555ff4e8cf8d45d4f262163d4c', NULL, '132.239.245.147', 1365698663, 1365698663),
	(5, 'alhsieh@ucsd.edu', 'alhsieh', NULL, '430dff259f49534f1e46c135352a6a5b', NULL, 'M', 'Y', '9783940739', NULL, 0.00, NULL, NULL, 1, 'Y', 'Y', '9ffb2c2a41d54e9eaa74c04633d28f82', NULL, '132.239.245.134', 1365716419, 1365716419),
	(6, 'dbmi@ucsd.edu', 'dbmi', NULL, 'e7fe8b88db51d86ef2f5e169144b9c1b', NULL, 'M', 'Y', '', NULL, 0.00, NULL, NULL, 1, 'Y', 'N', '85361645fb2ca62555680b5cb41a095c', NULL, '132.239.245.147', 1365720710, 1365720710),
	(7, 'ucsd_dbmi@ucsd.edu', 'ucsd_dbmi', NULL, 'e7fe8b88db51d86ef2f5e169144b9c1b', NULL, 'M', 'Y', '1234567890', NULL, 0.00, NULL, NULL, 1, 'Y', 'N', '6d2851407c8f4baf57c46fa6b6d9b066', NULL, '132.239.245.147', 1365737995, 1365737995),
	(8, 'ucsd_dbmi1@ucsd.edu', 'ucsd_dbmi1', NULL, 'e7fe8b88db51d86ef2f5e169144b9c1b', NULL, 'M', 'Y', '', NULL, 0.00, NULL, NULL, 1, 'Y', 'N', '2d4df59cee905ee0d1cab8453ea48461', NULL, '132.239.245.147', 1365738835, 1365738835),
	(9, 'ucsddbmi@ucsd.edu', 'ucsd', NULL, '41dfa16745e8ecf5fc6ef28f7986d683', NULL, 'M', 'Y', '', NULL, 0.00, NULL, NULL, 1, 'Y', 'N', '987deb24ef7d0a69bb981b26432cf707', NULL, '132.239.245.147', 1365742298, 1365742298),
	(10, 'abc@ucsd.edu', 'abcd', NULL, '41dfa16745e8ecf5fc6ef28f7986d683', NULL, 'M', 'Y', '', NULL, 0.00, NULL, NULL, 1, 'Y', 'N', '60caf5484cf5edc521749293c68f4eb6', NULL, '132.239.245.147', 1365742510, 1365742510),
	(11, 'dbmiucsd@ucsd.edu', 'dbmiucsd@ucsd.ed', NULL, '477f6b13dd6a9e4e061e3dec5fe43cfe', NULL, 'M', 'Y', '', NULL, 0.00, NULL, NULL, 1, 'Y', 'N', 'c47a4d93b05ae5ace398d9a0704736dd', NULL, '132.239.245.147', 1365742614, 1365742614),
	(12, 'b8sevqw3yu24xoo@hotmail.com', 'nikefreeskowqi', NULL, '912773d547cbe2ec125b1a261dbd1f0f', NULL, 'M', 'Y', 'Pineapple expres', NULL, 0.00, NULL, NULL, 3, 'Y', 'N', '9bd0fd22ff0fba0e397b20f7b87e47e0', NULL, '121.205.247.150', 1365998443, 1365998443);
/*!40000 ALTER TABLE `user` ENABLE KEYS */;
/*!40101 SET SQL_MODE=IFNULL(@OLD_SQL_MODE, '') */;
/*!40014 SET FOREIGN_KEY_CHECKS=IF(@OLD_FOREIGN_KEY_CHECKS IS NULL, 1, @OLD_FOREIGN_KEY_CHECKS) */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
